{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:48:32Z","timestamp":1790938112810,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1K23DK132505"],"award-info":[{"award-number":["1K23DK132505"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5R01DK135838"],"award-info":[{"award-number":["5R01DK135838"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"DOI":"10.1007\/s11606-026-10738-3","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:37:38Z","timestamp":1787686658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Receipt of Pharmacotherapy and Association with Healthcare Utilization Among US Adults with Alcohol or Opioid Use Disorder, 2022\u20132023"],"prefix":"10.1007","author":[{"given":"Daniel X.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Nagavally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-1356","authenticated-orcid":false,"given":"Laura C.","family":"Hawks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"10738_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric, A. and D.S.M.T.F. American Psychiatric Association, Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. DSM-5. 2013, Washington, D.C: American Psychiatric Association.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10738_CR2","doi-asserted-by":"crossref","unstructured":"Ringeisen H et al. Prevalence of Past-Year Mental and Substance Use Disorders, 2021-2022. Psychiatr Serv. 2025;76(8):720-728.","DOI":"10.1176\/appi.ps.20240329"},{"key":"10738_CR3","doi-asserted-by":"crossref","unstructured":"Shen J et al.\u00a0Prevalence, incidence, deaths, and disability-adjusted life-years of drug use disorders for 204 countries and territories during the past 30 years. Asian J Psychiatr. 2023;86:103677.","DOI":"10.1016\/j.ajp.2023.103677"},{"key":"10738_CR4","doi-asserted-by":"crossref","unstructured":"Kim S et al.\u00a0Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to 2040: a global time-series analysis and modelling study. EClinicalMedicine. 2025;\u00a079:102985.","DOI":"10.1016\/j.eclinm.2024.102985"},{"key":"10738_CR5","doi-asserted-by":"crossref","unstructured":"Kolla BP et al.\u00a0Infectious diseases occurring in the context of substance use disorders: A concise review. J Neurol Sci. 2020;\u00a0411:116719.","DOI":"10.1016\/j.jns.2020.116719"},{"key":"10738_CR6","doi-asserted-by":"crossref","unstructured":"Grant BF et al.\u00a0Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2016;\u00a073(1):39-47.","DOI":"10.1001\/jamapsychiatry.2015.2132"},{"key":"10738_CR7","doi-asserted-by":"crossref","unstructured":"Onaemo VN, Fawehinmi TO, D'Arcy C. Risk of suicide ideation in comorbid substance use disorder and major depression. PLoS One. 2022;\u00a017(12):e0265287.","DOI":"10.1371\/journal.pone.0265287"},{"key":"10738_CR8","doi-asserted-by":"crossref","unstructured":"Bohnert KM et al.\u00a0Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration. Addiction. 2017;\u00a0112(7):1193-1201.","DOI":"10.1111\/add.13774"},{"key":"10738_CR9","doi-asserted-by":"crossref","unstructured":"Giugovaz A, Grassi M, Marchetti I. Substance addictions and suicidal thoughts and behaviors: Evidence from a multi-wave epidemiological study. Psychiatry Res. 2024;\u00a0334:115821.","DOI":"10.1016\/j.psychres.2024.115821"},{"key":"10738_CR10","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez A et al. \u201cKnow your epidemic, know your response\u201d: Epidemiological assessment of the substance use disorder crisis in the United States. PLoS One. 2021;\u00a016(5):e0251502.","DOI":"10.1371\/journal.pone.0251502"},{"key":"10738_CR11","doi-asserted-by":"crossref","unstructured":"Li M et al.\u00a0Medical Costs of Substance Use Disorders in the US Employer-Sponsored Insurance Population. JAMA Netw Open. 2023;\u00a06(1):e2252378.","DOI":"10.1001\/jamanetworkopen.2022.52378"},{"key":"10738_CR12","doi-asserted-by":"crossref","unstructured":"Murphy SM.\u00a0The cost of opioid use disorder and the value of aversion. Drug Alcohol Depend. 2020;\u00a0217:108382.","DOI":"10.1016\/j.drugalcdep.2020.108382"},{"key":"10738_CR13","doi-asserted-by":"crossref","unstructured":"Peterson C et al.\u00a0Assessment of Annual Cost of Substance Use Disorder in US Hospitals. JAMA Netw Open. 2021;\u00a04(3):e210242.","DOI":"10.1001\/jamanetworkopen.2021.0242"},{"key":"10738_CR14","doi-asserted-by":"crossref","unstructured":"McPheeters M et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. Jama. 2023;\u00a0330(17):1653-1665.","DOI":"10.1001\/jama.2023.19761"},{"key":"10738_CR15","doi-asserted-by":"crossref","unstructured":"Ray LA et al.\u00a0Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;\u00a03(6):e208279.","DOI":"10.1001\/jamanetworkopen.2020.8279"},{"key":"10738_CR16","unstructured":"Poorman E, McQuade BM, Messmer S.\u00a0Medications for Alcohol Use Disorder. Am Fam Physician. 2024;\u00a0109(1):71-78."},{"key":"10738_CR17","unstructured":"Mar Y et al.\u00a0New York State Department of Health AIDS Institute Clinical Guidelines, in Treatment of Alcohol Use Disorder. 2023, Johns Hopkins University: Baltimore (MD)."},{"key":"10738_CR18","doi-asserted-by":"crossref","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;\u00a014(2S Suppl 1):1\u201391.","DOI":"10.1097\/ADM.0000000000000633"},{"key":"10738_CR19","doi-asserted-by":"crossref","unstructured":"Gibson A et al. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;\u00a0103(3):462-8.","DOI":"10.1111\/j.1360-0443.2007.02090.x"},{"key":"10738_CR20","doi-asserted-by":"crossref","unstructured":"Bernstein EY et al.\u00a0Outcomes After Initiation of Medications for Alcohol Use Disorder at Hospital Discharge. JAMA Netw Open. 2024;\u00a07(3):e243387.","DOI":"10.1001\/jamanetworkopen.2024.3387"},{"key":"10738_CR21","doi-asserted-by":"crossref","unstructured":"Onuoha EN et al.\u00a0Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review. Value Health. 2021;\u00a024(7):1068-1083.","DOI":"10.1016\/j.jval.2020.12.023"},{"key":"10738_CR22","doi-asserted-by":"crossref","unstructured":"Murphy SM, Polsky D. Economic Evaluations of Opioid Use Disorder Interventions. Pharmacoeconomics. 2016;\u00a034(9):863-87.","DOI":"10.1007\/s40273-016-0400-5"},{"key":"10738_CR23","doi-asserted-by":"crossref","unstructured":"Dowell D et al.\u00a0Treatment for Opioid Use Disorder: Population Estimates - United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;\u00a073(25):567-574.","DOI":"10.15585\/mmwr.mm7325a1"},{"key":"10738_CR24","unstructured":"National Institute on Alcohol Abuse and Alcoholism. Alcohol Treatment in the United States. March 2026; Available from: https:\/\/www.niaaa.nih.gov\/alcohols-effects-health\/alcohol-topics-z\/alcohol-facts-and-statistics\/alcohol-treatment-united-states."},{"key":"10738_CR25","doi-asserted-by":"crossref","unstructured":"Liu L, Zhang C, Nahata MC.\u00a0Trends in Treatment Need and Receipt for Substance Use Disorders in the US. JAMA Netw Open. 2025;\u00a08(1):e2453317.","DOI":"10.1001\/jamanetworkopen.2024.53317"},{"key":"10738_CR26","doi-asserted-by":"crossref","unstructured":"Saini J, Johnson B, Qato DM.\u00a0Self-Reported Treatment Need and Barriers to Care for Adults With Opioid Use Disorder: The US National Survey on Drug Use and Health, 2015 to 2019. Am J Public Health. 2022;\u00a0112(2):284-295.","DOI":"10.2105\/AJPH.2021.306577"},{"key":"10738_CR27","unstructured":"Center for Behavioral Health Statistics and Quality, 2023 National Survey on Drug Use and Health Public Use File Codebook, Substance Abuse and Mental Health Services Administration, Editor. 2024: Rockville, MD."},{"key":"10738_CR28","unstructured":"Quality CfBHSa.\u00a02023 National Survey on Drug Use and health (NSDUH): Methodological summary and definitions. 2024, Substance Abuse and Mental Health Services Administration: Rockville, MD."},{"key":"10738_CR29","unstructured":"Quality CfBHSa. 2023 National Survey on Drug use and Health Final Analytic File Codebook. 2024, Substance Abuse and Mental Health Services Administration: Rockville, MD. p. 603."},{"key":"10738_CR30","doi-asserted-by":"crossref","unstructured":"Evoy KE et al.\u00a0National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. J Subst Abuse Treat. 2020;\u00a0119:108141.","DOI":"10.1016\/j.jsat.2020.108141"},{"key":"10738_CR31","doi-asserted-by":"crossref","unstructured":"Han B et al.\u00a0Use of Medications for Alcohol Use Disorder in the US: Results From the 2019 National Survey on Drug Use and Health. JAMA Psychiatry. 2021;\u00a078(8):922-4.","DOI":"10.1001\/jamapsychiatry.2021.1271"},{"key":"10738_CR32","doi-asserted-by":"crossref","unstructured":"Jones CM et al.\u00a0Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021. JAMA Netw Open. 2023;\u00a06(8):e2327488.","DOI":"10.1001\/jamanetworkopen.2023.27488"},{"key":"10738_CR33","doi-asserted-by":"crossref","unstructured":"Kennedy-Hendricks A et al.\u00a0News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic. Health Aff (Millwood). 2019;\u00a038(4):643-651.","DOI":"10.1377\/hlthaff.2018.05075"},{"key":"10738_CR34","doi-asserted-by":"crossref","unstructured":"McGinty EE et al.\u00a0U.S. news media coverage of solutions to the opioid crisis, 2013\u20132017. Prev Med. 2019;\u00a0126:105771.","DOI":"10.1016\/j.ypmed.2019.105771"},{"key":"10738_CR35","doi-asserted-by":"crossref","unstructured":"Christine PJ et al.\u00a0Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder. JAMA Health Forum. 2023;\u00a04(10):e233549.","DOI":"10.1001\/jamahealthforum.2023.3549"},{"key":"10738_CR36","doi-asserted-by":"crossref","unstructured":"Saloner B et al.\u00a0Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act. Subst Abus. 2023;\u00a044(3):108-111.","DOI":"10.1177\/08897077231186212"},{"key":"10738_CR37","doi-asserted-by":"crossref","unstructured":"Lindenfeld Z et al. Examining the Potential Role of Opioid Settlement Funds in the Face of Impending Federal Budget Reductions for Substance Use Disorders. Health Services Research. 2026;\u00a061(2):e70094.","DOI":"10.1111\/1475-6773.70094"},{"key":"10738_CR38","doi-asserted-by":"crossref","unstructured":"Marshall BDL, Pendergrass K, Whaley S. Maximizing the Public Health Benefits of Opioid Settlements: Policy Recommendations for Equity, Sustainability, and Impact. Milbank Q. 2025;\u00a0103(S1):105-123.","DOI":"10.1111\/1468-0009.70036"},{"key":"10738_CR39","unstructured":"Donohue JM et al. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. Jama. 2021;\u00a0326(2):154-164."},{"key":"10738_CR40","doi-asserted-by":"crossref","unstructured":"Barnett ML et al.\u00a0Racial Inequality in Receipt of Medications for Opioid Use Disorder. N Engl J Med. 2023;\u00a0388(19):1779-1789.","DOI":"10.1056\/NEJMsa2212412"},{"key":"10738_CR41","doi-asserted-by":"crossref","unstructured":"Englander H et al.\u00a0A Call to Action: Hospitalists\u2019 Role in Addressing Substance Use Disorder. J Hosp Med. 2020;\u00a015(3):184-187.","DOI":"10.12788\/jhm.3311"},{"key":"10738_CR42","doi-asserted-by":"crossref","unstructured":"Singh JA, Cleveland JD.\u00a0Trends in Hospitalizations for Alcohol Use Disorder in the US From 1998 to 2016. JAMA Netw Open. 2020;\u00a03(9):e2016580.","DOI":"10.1001\/jamanetworkopen.2020.16580"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10738-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:37:41Z","timestamp":1787686661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10738-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":42,"alternative-id":["10738"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10738-3","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to report.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}